MedPath

Oral antimicrobial treatment vs. outpatient parenteral for infective endocarditis

Phase 4
Not yet recruiting
Conditions
Infective endocarditis
Registration Number
2024-519969-21-00
Lead Sponsor
Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer
Brief Summary

To demonstrate the non-inferiority of outpatient oral antibiotic therapy in comparison with outpatient parenteral antibiotic treatment (OPAT)

Detailed Description

Not available

Recruitment & Eligibility

Status
Authorised, recruitment pending
Sex
Not specified
Target Recruitment
342
Inclusion Criteria

Left-sided native or prosthetic infective endocarditis based on the modified Duke criteria infected with one of the following nonresistant microorganisms: Non-resistant streptococci and other gram positive cocci,e.g., Granulicatella and Abiotrophia; Enterococcus faecalis; Staphylococcus aureus;coagulase-negative staphylococci and HACEK group.

Male or female 18 years old or older.

≥10 days of appropriate parenteral antibiotic treatment overall and at least one week of appropriate parenteral treatment after valve surgery

T<38.0° C for more than two days

C-reactive protein dropped below 25% of the peak value or below an absolute value of 20 mg/L, and the white blood cell count dropped to less than 15 × 10(9)/L during antibiotic treatment

No sign of abscess formation revealed by echocardiography

Transthoracic/transesophageal echocardiography performed preferably within 48 h of randomization. Ecoscopy or portable echocardiogram are also admitted, as long as they are registered on the clinical history.

Exclusion Criteria

Body mass index >40

Women in lactancy period

Concomitant infection requiring intravenous antibiotic therapy

Inability to give informed consent to participation

Suspicion of reduced absorption of oral treatment due to abdominal disorder

Microorganisms other than those defined in inclusion criteria

Any immunosuppressive disease or any medical condition at the discretion of the investigator that may preclude oral or OPAT therapy

No family or appropriate home support

Reduced compliance

Women of childbearing potential with a positive pregnancy test, or participants (male or female) who wish to plan a pregnancy during the trial period.

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Composite endpoint (whatever happen first) of unplanned hospitalization due to any reason, all-cause mortality, unplanned cardiac surgery and IE relapse within six months from diagnosis

Composite endpoint (whatever happen first) of unplanned hospitalization due to any reason, all-cause mortality, unplanned cardiac surgery and IE relapse within six months from diagnosis

Secondary Outcome Measures
NameTimeMethod
To evaluate quality of life and patient satisfaction

To evaluate quality of life and patient satisfaction

To evaluate costs of both interventions through a pharmacoeconomic analysis.

To evaluate costs of both interventions through a pharmacoeconomic analysis.

To evaluate number complications related to parenteral administration and oral administration of antibiotics (such as catheter related infections, Cl difficile diarrhea,among others).

To evaluate number complications related to parenteral administration and oral administration of antibiotics (such as catheter related infections, Cl difficile diarrhea,among others).

Unplanned hospitalization, all-cause mortality, unplanned cardiac surgery and relapse of IE rates for each variable

Unplanned hospitalization, all-cause mortality, unplanned cardiac surgery and relapse of IE rates for each variable

Trial Locations

Locations (9)

Hospital General Alicante

🇪🇸

Alicante, Spain

Hospital Universitario De Cruces

🇪🇸

Barakaldo, Spain

University Hospital Virgen Del Rocio S.L.

🇪🇸

Sevilla, Spain

Bellvitge University Hospital

🇪🇸

L'Hospitalet De Llobregat, Spain

Consorci Sanitari De Terrassa

🇪🇸

Terrassa, Spain

Hospital General Universitario Gregorio Maranon

🇪🇸

Madrid, Spain

Hospital Clinic De Barcelona

🇪🇸

Barcelona, Spain

Hospital Universitario De Canarias

🇪🇸

San Cristobal De La Laguna, Spain

Hospital Universitario de Donostia

🇪🇸

Gipuzkoa, Spain

Hospital General Alicante
🇪🇸Alicante, Spain
Esperanza Merino
Site contact
+34966389146
merino_luc@gva.es

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.